Baxter International Inc (BAX)

Baxter International Inc. has issued a recall for two lots of its 0.9% Sodium Chloride Injection due to potential fiberglass contamination. The FDA warns that intravenous administration of solutions containing fiberglass could lead to serious health consequences, including blood clots, organ damage, or death, though no adverse effects have been reported yet. The affected products were distributed to healthcare providers in over a dozen states, including Texas, between July 31 and August 3, 2026.

Gartner advises healthcare Chief Supply Chain Officers (CSCOs) to replace manual inventory counting with autonomous supply rooms utilizing computer vision and artificial intelligence. These AI-driven rooms autonomously monitor inventory, predict demand, and trigger reorders, freeing up clinical staff from manual tasks. Gartner emphasizes evaluating new technologies based on their ability to eliminate physical labor rather than just speeding it up, allowing nurses more time with patients.

Baxter International Inc. has voluntarily recalled three injectable drugs due to potential contamination with fiberglass or stainless steel particles. The recalled products include a 70% Dextrose Injection, a 0.9% Sodium Chloride Injection, and an Anticoagulant Sodium Citrate Solution, which was distributed to only one customer. These contaminants could lead to serious health issues such as blockages, clotting, and tissue or organ damage if injected.

Baxter International Inc. (BAX) stock decreased by 2.15% to $25.93 on Thursday, despite a generally favorable trading session for the broader market. The S&P 500 Index and Dow Jones Industrial Average both saw gains. The company's stock closed 13.57% below its 52-week high of $30.00.

Baxter International has issued a recall for one lot of its 70% Dextrose Injection after stainless steel particles were discovered in the solution. This is the third particulate recall for an intravenous product in about a month, impacting primarily home parenteral nutrition patients as the product is used in compounded solutions. The affected lot was distributed regionally in Alabama, Georgia, and Tennessee, and patients are advised to contact their compounding pharmacy to determine if their solutions are affected.